CYP19A1 and heart failure: Aromatase inhibitors were associated with increased risks of heart failure (HR, 1.86 [95% CI, 1.14-3.03]) and cardiovascular mortality (HR, 1.50 [95% CI, 1.11-2.04]) compared with tamoxifen